Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Sunitinib

Criteria

Inclusion Criteria:

• Histologically or cytologically proven diagnosis of breast cancer

• Metastatic or locally recurrent disease that is, in the opinion of the investigator, not amenable to resection or radiation therapy

• Patients with at least one measurable lesion as per RECIST

Exclusion Criteria:

• Inflammatory breast cancer

• Prior treatment with VEGF inhibitors (unless in adjuvant setting at least 12 months ago)